<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906187</url>
  </required_header>
  <id_info>
    <org_study_id>IB 2020-04</org_study_id>
    <secondary_id>2020-A02767-32</secondary_id>
    <nct_id>NCT04906187</nct_id>
  </id_info>
  <brief_title>Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery</brief_title>
  <acronym>MONIALC</acronym>
  <official_title>Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery. The MONIALC Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, phase II, non-comparative, single-blind clinical study&#xD;
      that will determine whether morphine reduction through intraoperative monitoring by ANI&#xD;
      (Analgesia Nociception Index) significantly reduces chronic post-surgical pain at three&#xD;
      months after laparotomy for ovarian carcinoma with regard to standard care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to carrying out the research, the informed consent of the person must be obtained after&#xD;
      being informed of the purpose of the research, its conduct and duration, benefits, potential&#xD;
      risks and constraints of the study.&#xD;
&#xD;
      Before inclusion,all eligibility criteria will be verified, VAS pain score and VAS anxiety&#xD;
      will be performed.&#xD;
&#xD;
      The surgical procedure for ovarian carcinoma will be performed by laparotomy and the&#xD;
      intraoperative monitoring of nociception wil depend of the randomization arm : Intraoperative&#xD;
      ANI monitoring of nociception (experimental arm) versus no specific monitoring of nociception&#xD;
      (control arm). The total dose of opioids (in micrograms) received by the patients will be&#xD;
      recorded at the end of the surgery.&#xD;
&#xD;
      VAS pain score will be performed immediately postoperatively and at three months after the&#xD;
      intervention. A DN4 questionnaire (neuropathic pain) will be evaluated at three months after&#xD;
      the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 25, 2021</start_date>
  <completion_date type="Anticipated">August 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a pain score on the self-assessment VAS &gt; 4, three months after the surgery.</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>The Visual Analog Scale (VAS) is a validated, reliable and reproducible tool. The VAS will be used to measure pain. This self-assessment scale allows the patient to evaluate his or her pain from 0 to 10 &quot;0=No pain&quot; to &quot;10=Maximum imaginable pain &quot;. A pain VAS score of 4 and above is considered clinically significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arm A : total dose of opioids received intraoperatively</measure>
    <time_frame>Surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm B : total dose of opioids received intraoperatively</measure>
    <time_frame>Surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm A : Patients' pain score on the VAS immediately postoperatively</measure>
    <time_frame>within one hour of extubation</time_frame>
    <description>The Visual Analog Scale (VAS) is a validated, reliable and reproducible tool. The VAS will be used to measure pain. This self-assessment scale allows the patient to evaluate his or her pain from 0 to 10 &quot;0=No pain&quot; to &quot;10=Maximum imaginable pain &quot;. A pain VAS score of 4 and above is considered clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm B : Patients' pain score on the VAS immediately postoperatively</measure>
    <time_frame>within one hour of extubation</time_frame>
    <description>The Visual Analog Scale (VAS) is a validated, reliable and reproducible tool. The VAS will be used to measure pain. This self-assessment scale allows the patient to evaluate his or her pain from 0 to 10 &quot;0=No pain&quot; to &quot;10=Maximum imaginable pain &quot;. A pain VAS score of 4 and above is considered clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm A : proportion of patients with a DN4 questionnaire score&gt; 4, three months after surgery</measure>
    <time_frame>3 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm B : Arm A : proportion of patients with a DN4 questionnaire score&gt; 4, three months after surgery</measure>
    <time_frame>3 months after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Ovarian Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm A : Experimental group with intraoperative ANI monitoring of nociception</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : Control group without ANI intraoperative monitoring of nociception</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arm A : intraoperative ANI monitoring of nociception</intervention_name>
    <description>For the experimental group (arm A), the sufentanil doses are adjusted to maintain an ANI between 50 and 70. Morphine doses are adjusted from 0.05 to 0.05 µg / ml. Intraoperative data will be collected for ANI, TIVA and hemodynamics.</description>
    <arm_group_label>Arm A : Experimental group with intraoperative ANI monitoring of nociception</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Arm B : no specific monitoring of nociception</intervention_name>
    <description>For the control group (arm B), adjustments to the opioid doses are made in relation to the hemodynamic reactions of the patient and the operating times. Intraoperative data will be collected for TIVA and hemodynamics.</description>
    <arm_group_label>Arm B : Control group without ANI intraoperative monitoring of nociception</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Woman aged 18 years and over.&#xD;
&#xD;
          2. Histologically proven ovarian carcinoma.&#xD;
&#xD;
          3. Indication for laparotomy surgery with xyphopubic incision.&#xD;
&#xD;
          4. Acceptance of epidural anesthesia.&#xD;
&#xD;
          5. Pain score ≤ 3 (VAS or Numeric Verbal Scale).&#xD;
&#xD;
          6. Free and informed consent.&#xD;
&#xD;
          7. Patient affiliated with a French social security scheme in accordance with French law&#xD;
             on research involving human participants.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Heart rhythm disturbances.&#xD;
&#xD;
          2. History of Cerebral Vascular Accident (CVA).&#xD;
&#xD;
          3. History of epilepsy.&#xD;
&#xD;
          4. Wearing a pacemaker.&#xD;
&#xD;
          5. Receiving morphine treatment preoperatively.&#xD;
&#xD;
          6. Medical contraindication to an epidural.&#xD;
&#xD;
          7. Patient unable to follow and adhere to trial procedures for geographic, social or&#xD;
             psychological reasons.&#xD;
&#xD;
          8. Patient placed under guardianship or curatorship.&#xD;
&#xD;
          9. Patient already included in the present study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arnaud DUBUISSON, Nurse</last_name>
    <phone>(0)5.56.33.37.30</phone>
    <phone_ext>+33</phone_ext>
    <email>a.dubuisson@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone MATHOULIN-PELISSIER, MD, PhD</last_name>
    <email>s.mathoulin@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Arnaud DUBUISSON, Nurse</last_name>
      <email>a.dubuisson@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian neoplasm</keyword>
  <keyword>analgesia monitoring</keyword>
  <keyword>pain measurement</keyword>
  <keyword>Analgesia Nociception Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

